Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (20203)	4/27/2004 4:23:34 PM
From: rrufff	Respond to of 120409

AEDU - .48 + .12 This is another one that requires LOTS of patience. It's education and has had great wins and write-ups. It's expenses have been cut to the bone and it has a very tight capital structure. Almost no PR's and it will be asleep. One of these days, educational computerization and modernization will be in vogue and this will be a 10 bagger IMO.

To: GARY P GROBBEL who wrote (20203)	4/28/2004 8:23:20 AM
From: rrufff	Respond to of 120409

CRKT - loses the "E" - files 10-K

To: GARY P GROBBEL who wrote (20203)	4/28/2004 8:43:16 AM
From: rrufff	Read Replies (1) \| Respond to of 120409

CTE - still on sale has a PR this morning. CardioTech's AlgiMed(TM) Dressing Receives Approval for Medicare Reimbursement PR Newswire - April 28, 2004 08:30 WOBURN, Mass., Apr 28, 2004 /PRNewswire-FirstCall via COMTEX/ -- CardioTech International, Inc. (Amex: CTE) today announced that on April 6, 2004 the Centers for Medicare and Medicaid Services (CMS) granted AlgiMed a Medicare billing code A6196 described as "alginate dressing, wound cover, pad size 16 sq. in or less." This approval enables CardioTech customers to be reimbursed by Medicare for the use of AlgiMed wound dressings. Advanced wound care is a $1.5 billion market consisting of specialized dressings to treat serious wounds employing the principle of moist wound healing. By maintaining a moist wound-healing environment wounds have been shown to heal faster, with reduced pain and minimal scarring. AlgiMed wound dressings are designed for exudating and bleeding wounds. The dressing absorbs wound exudate almost instantaneously, and helps control minor bleeding. AlgiMed is a sterile wound dressing made of calcium alginate. When the dressing comes in contact with blood, calcium (a potent procoagulant) is released, thus stopping bleeding. AlgiMed complements HydroMed in the wound care continuum. CardioTech's other wound dressing, HydroMed is an absorbent hydrogel dressing designed for low exudating wounds, while AlgiMed is an alginate dressing designed for moderately exudating and bleeding wounds. AlgiMed will be distributed by CardioTech through its own warehouse facilities in Massachusetts and California. The dressings will be sold through sales representatives in the U.S., and by national distributors overseas. Dr. Michael Szycher, CEO and Chairman of CardioTech, commented: "We now have Medicare reimbursement for our HydroMed and AlgiMed wound dressings. Medicare reimbursement is critical to our overall sales strategy and puts us in advantageous position as we prepare to execute orders in the U.S. market." About CardioTech: CardioTech develops, manufactures and markets differentiated medical devices. Revenue sources include devices used in cardiopulmonary bypass (heart-lung), and OEM products manufactured for Fortune 100 companies. CardioTech's wound dressings address a combined $600 million annual market. CardioTech is the only company in the world developing a synthetic coronary artery bypass graft that addresses a potential market of $1.5 billion annually. Additionally, CardioTech has partnered with Implant Sciences and CorNova to develop a drug-eluting stent that addresses a $1 billion market. CardioTech believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review CardioTech's filings with the Securities and Exchange Commission.

To: GARY P GROBBEL who wrote (20203)	4/30/2004 11:57:16 AM
From: GARY P GROBBEL	Respond to of 120409

PHPG...this is prior post below...esp read the one ref contract for components of anti-missile system...then look at this news story below from yest. I am NOT saying PHPG will get this...but it sure looks close...and if this was approved by the Congress there would probably be 3-4 major suppliers due to huge cost and logistics involved..any if ANY of this stuff pops there are only 5.3m shares out: Congress and anti-missile system: kron4.com Prior Post and PR's: PHPG 1.30..these are the pr's from last couple of weeks..i would own some of this and just wait..note that the company had not had any pr's since their last acq in Dec...they state in the year end release they are well set for growth this year.....fact that we have had 3 pr's in 3 weeks leads me to believe they fell they are on track...and very few companies out there have all the capabilities PHPG has...esp in the defense area which is a major part of their business... biz.yahoo.com biz.yahoo.com biz.yahoo.com